{"title":"FDA panel debates SSRI risk label; APA raises concerns","authors":"Valerie A. Canady","doi":"10.1002/mhw.34565","DOIUrl":null,"url":null,"abstract":"<p>A recent Food and Drug Administration (FDA) expert panel meeting has reignited debate over the safety of selective serotonin reuptake inhibitors (SSRIs) during pregnancy, with discussions centering on whether to add a Black Box warning to these commonly prescribed antidepressants.</p>","PeriodicalId":100916,"journal":{"name":"Mental Health Weekly","volume":"35 33","pages":"3-4"},"PeriodicalIF":0.0000,"publicationDate":"2025-08-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Mental Health Weekly","FirstCategoryId":"1085","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/mhw.34565","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
A recent Food and Drug Administration (FDA) expert panel meeting has reignited debate over the safety of selective serotonin reuptake inhibitors (SSRIs) during pregnancy, with discussions centering on whether to add a Black Box warning to these commonly prescribed antidepressants.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
